RT journal article
T1 Necrolytic migratory erythema associated with glucagonoma treated successfully with cyclosporine
A1 Jiménez Gallo, David
A1 Ossorio García, Lidia
A1 De la Varga Martínez, Raquel
A1 Arjona Aguilera, Cintia
A1 Linares Barrios, Mario Dionisio
A2 Medicina
AB Glucagonoma syndrome is a rare paraneoplastic syndrome characterized by elevated serum levels of glucagon, the presence of glucagonoma, and dermatological clinical findings such as necrolyticmigratory erythema (NME) (John & Schwartz, 2016; Luber, Ackerman, Culpepper, Buschmann, & Koep, 2016). The main challengeassociated with the diagnosis of glucagonoma syndrome is that atdiagnosis, metastasis has already occurred in more than 50% ofcases. However, this tumor tends to exhibit slow growth; mediansurvival is 3–7 years and patients have survived for up to 24 years(John & Schwartz, 2016; Mendoza-Guil, Hern andez-Jurado, Burkhardt, Linares, & Naranjo, 2005). Furthermore, NME significantlyaffects patients’ quality of life and is characteristically resistant totreatment (Thomaidou, Nahmias, Gilead, Zlotogorski, & Ramot,2016). In this sense, additional knowledge regarding effective drugsfor treating persistent NME is needed.
PB Wiley
SN 1529-8019
YR 2017
FD 2017
LK http://hdl.handle.net/10498/36540
UL http://hdl.handle.net/10498/36540
LA eng
DS Repositorio Institucional de la Universidad de Cádiz
RD 10-may-2026